DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Friday morning. The brokerage issued a hold rating on the stock.

Several other research analysts have also recently issued reports on DBVT. HC Wainwright reissued a buy rating and set a $5.00 price target on shares of DBV Technologies in a report on Thursday. JMP Securities increased their price target on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a report on Wednesday.

DBV Technologies Trading Up 2.1 %

DBV Technologies stock opened at $0.97 on Friday. The stock has a market cap of $93.60 million, a P/E ratio of -1.12 and a beta of 0.68. The company has a fifty day simple moving average of $0.91 and a 200-day simple moving average of $1.32. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $3.70.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. During the same period last year, the firm earned ($0.26) earnings per share. As a group, sell-side analysts forecast that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.